Navigation Links
OncoSec Medical Announces $7.2 Million Public Offering
Date:12/13/2012

SAN DIEGO, Dec. 13, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $7.2 million of securities in a registered public offering. OncoSec has agreed to sell to institutional investors an aggregate of 28,800,000 shares of its common stock at $0.25 per share. Additionally, investors will receive warrants to purchase up to 14,400,000 shares of common stock at an exercise price of $0.26 per share for a term of four years.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

The gross proceeds of the offering are expected to be approximately $7.2 million. Net proceeds, after deducting the placement agent's fee and other estimated offering expenses payable by OncoSec, are expected to be approximately $6.5 million.

OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.

Dawson James Securities, Inc. acted as the exclusive placement agent for the transaction.  Burrill LLC and Noble Financial Capital Markets acted as financial advisors to OncoSec in connection with the transaction.

The offering is expected to close on December 17, 2012, subject to customary closing conditions.

The securities described above are being offered by OncoSec pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission, or the SEC. A prospectus supplement related to the offering will be filed with the SEC. The securities may only be offered by means of a prospectus. Copies of the prospectus and prospectus supplement can be obtained directly from OncoSec and at the
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW ... for operable and inoperable solid tumor cancers, announced today that ... th Annual Phacilitate Immunotherapy Forum in Washington ... will take place on January 26 at 10:30 a.m. EST ...
(Date:1/23/2015)... PHILADELPHIA , Jan. 23, 2015  Pete Rose, baseball,s all-time ... joint and arthritis pain reliever Myoflex, Ducere Pharma has announced. ... and we are excited to have him on board with ... . "He is a legendary player who is known across ...
(Date:1/23/2015)... LAS VEGAS , Jan. 23, 2015 Cord Blood ... CBAI ) ("CBAI" or the "Company")  filed a Preliminary Proxy ... ( www.sec.gov ) today, and provides an update for shareholders ... authorized shares is requested. Dear Shareholders, ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... , NANJING , China , ... SCR ) ("Simcere" or the "Company"), a leading manufacturer and supplier,of ... the annual general meeting of shareholders (the "Meeting") will be held,on ... Beijing time, at No.699-18, Xuanwu,Avenue, Xuanwu District, Nanjing ...
... - Group Revenues in the Second Quarter up by 6.8% (Excluding, ... in, the Cosmetics and Life Science Research Segments, ... Operations More Than Doubled to EUR 24.8m, - Revenue Guidance for 2010 Specified ... , , ...
Cached Medicine Technology:Simcere Pharmaceutical Group Provides Notice of Annual General Meeting 2Substantial Revenues and Earnings Plus for Gerresheimer 2Substantial Revenues and Earnings Plus for Gerresheimer 3Substantial Revenues and Earnings Plus for Gerresheimer 4Substantial Revenues and Earnings Plus for Gerresheimer 5
(Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... 22, 2015 Four years since the release of ... coincided with the marriage of Avasa & Matthew Love – the ... is scheduled for release through White Swan Records on February 24, ... is a sacred path available to all of us to walk ...
(Date:1/22/2015)... January 22, 2015 JJsHouse.com is a famous ... Today, the business announces its latest collection of wedding ... “The most important issue is the wedding dress on your ... in a woman’s life. Every bride wants to find the ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX -,News), an ... to develop novel formulations of drugs, is ... Indaflex(TM), its topical NSAID,(Non-Steroidal Anti-Inflammatory Drug) formulation, ... ("Cypress,) (NASDAQ: CYPB )., In ...
... May 12 portionpals(R), an innovative,weight-loss tool is proud ... mark,this past Saturday, May 10th, in less than its ... alternative among consumers,looking for a healthy way to lose ... share in a multi-billion dollar industry with no national,distribution ...
... N.J., May 12 Medarex, Inc.,(Nasdaq: MEDX ) announced ... Including a gain of $151.8 million, or $1.19 per ... stock in February 2008, Medarex,s,net income for the quarter ended ... compared to a net income of $110.3 million, or $0.88,per ...
... MedCath Corporation,(Nasdaq: MDTH ), a health care ... the diagnosis and treatment of cardiovascular,disease, today announced ... Interim Chief Financial Officer, has been named,Senior Vice-President, ... new role, Art will continue to oversee and ...
... The American,Veterinary Medical Association (AVMA) has revised its ... veterinarians with additional guidance,for managing pain associated with ... 2008, does not dictate that practitioners use any,particular ... provides some,basic recommendations for consideration by practitioners when ...
... Authority Over Tobacco, WASHINGTON, May 9 ... today announces their,support of H.R. 1108, "The Family ... FDA regulatory authority over tobacco products., "We ... year.,H.R. 1108 has broad bi-partisan support and could ...
Cached Medicine News:Health News:AlphaRx's Indaflex(TM) Continues its Clinical Development 2Health News:Diet Industry Newcomer Hits the 1 Million Unit Mark 2Health News:Medarex Announces 2008 First Quarter Financial Results 2Health News:Medarex Announces 2008 First Quarter Financial Results 3Health News:Medarex Announces 2008 First Quarter Financial Results 4Health News:Medarex Announces 2008 First Quarter Financial Results 5Health News:Medarex Announces 2008 First Quarter Financial Results 6Health News:Medarex Announces 2008 First Quarter Financial Results 7Health News:Medarex Announces 2008 First Quarter Financial Results 8Health News:MedCath Names Parker to New Finance Post 2Health News:Revised AVMA Policy on Castrating and Dehorning Cattle Provides Additional Guidance for Managing Pain 2
... the only approved radiolucent stand-alone implant that ... the proven reliability of the BAK threaded ... is constructed of radiolucent, carbon-fiber reinforced PEEK-OPTIMA ... visualization, providing a new level of confidence ...
... (bDNA) delivers unmatched precision and reproducibility, so you ... viral load values they can trust.,you detect significant ... critical decision points - without the variability seen ... to choose VERSANT HIV bDNA, consider this: it's ...
... The AMPLICOR HIV-1 MONITOR Test, v1.5, an FDA-approved ... load testing, has been used in the regulatory ... in eight out of 10 clinical laboratories worldwide. ... v1.5 is an in vitro nucleic acid amplification ...
... Recombigen HIV is a single use rapid test, ... plasma, serum and whole blood (venipuncture). Uni-Gold Recombigen ... care settings as an aid in diagnosis of ... use in appropriate multi-test algorithms designed for the ...
Medicine Products: